Dacomitinib (PF-00299804), an irreversible pan-her tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers
P. Janne
Dacomitinib (PF-00299804), an irreversible pan-her tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers
P. Janne